S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:BMEA

Biomea Fusion (BMEA) Stock Forecast, Price & News

$33.96
+0.10 (+0.30%)
(As of 05/31/2023 ET)
Compare
Today's Range
$32.82
$34.93
50-Day Range
$15.43
$33.99
52-Week Range
$4.41
$36.68
Volume
1.13 million shs
Average Volume
619,361 shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.29

Biomea Fusion MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
18.6% Upside
$40.29 Price Target
Short Interest
Bearish
19.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$12 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.54) to ($3.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

715th out of 1,006 stocks

Pharmaceutical Preparations Industry

361st out of 492 stocks


BMEA stock logo

About Biomea Fusion (NASDAQ:BMEA) Stock

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

BMEA Stock News Headlines

Biomea: Novel Approach To Diabetes And Cancer
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Biomea Fusion (NASDAQ:BMEA) Coverage Initiated at Barclays
Recap: Biomea Fusion Q1 Earnings
BMEA Biomea Fusion, Inc.
Biomea Fusion (NASDAQ:BMEA) PT Lowered to $37.00
See More Headlines
Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

BMEA Company Calendar

Last Earnings
3/28/2023
Today
6/01/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BMEA
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.29
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+18.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-81,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.35 per share

Miscellaneous

Free Float
19,222,000
Market Cap
$1.20 billion
Optionable
Not Optionable
Beta
-1.04

Key Executives

  • Mr. Thomas Andrew Butler (Age 41)
    Co-Founder, Chairman & CEO
    Comp: $772.86k
  • Mr. Ramses M. ErdtmannMr. Ramses M. Erdtmann (Age 59)
    Co-Founder, Pres, COO & Director
    Comp: $570.57k
  • Mr. Franco ValleMr. Franco Valle (Age 41)
    CFO & Principal Accounting Officer
    Comp: $251.69k
  • Mr. Heow Tan (Age 63)
    Chief Technology & Quality Officer
  • Ms. Naomi Cretcher
    Chief People Officer
  • Dr. Thorsten Kirschberg Ph.D. (Age 52)
    Exec. VP of Chemistry
  • Dr. Stephan Morris M.D.
    Chief Medical Officer
  • Mr. Ravi Upasani
    Sr. VP of Intellectual Property













BMEA Stock - Frequently Asked Questions

Should I buy or sell Biomea Fusion stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMEA shares.
View BMEA analyst ratings
or view top-rated stocks.

What is Biomea Fusion's stock price forecast for 2023?

7 equities research analysts have issued 12 month target prices for Biomea Fusion's stock. Their BMEA share price forecasts range from $22.00 to $53.00. On average, they anticipate the company's share price to reach $40.29 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price.
View analysts price targets for BMEA
or view top-rated stocks among Wall Street analysts.

How have BMEA shares performed in 2023?

Biomea Fusion's stock was trading at $8.43 on January 1st, 2023. Since then, BMEA stock has increased by 302.8% and is now trading at $33.96.
View the best growth stocks for 2023 here
.

When is Biomea Fusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our BMEA earnings forecast
.

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) posted its quarterly earnings results on Tuesday, March, 28th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.05.

What ETFs hold Biomea Fusion's stock?

ETFs with the largest weight of Biomea Fusion (NASDAQ:BMEA) stock in their portfolio include BlackRock Future Health ETF (BMED), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB),

When did Biomea Fusion IPO?

(BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO.

What is Biomea Fusion's stock symbol?

Biomea Fusion trades on the NASDAQ under the ticker symbol "BMEA."

Who are Biomea Fusion's major shareholders?

Biomea Fusion's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (7.57%), Baker BROS. Advisors LP (5.97%), BlackRock Inc. (2.78%), Perceptive Advisors LLC (0.92%), Geode Capital Management LLC (0.60%) and JPMorgan Chase & Co. (0.47%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Global Healthcare Ma Cormorant, Michael JM Hitchcock and Rainer M Erdtmann.
View institutional ownership trends
.

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomea Fusion's stock price today?

One share of BMEA stock can currently be purchased for approximately $33.96.

How much money does Biomea Fusion make?

Biomea Fusion (NASDAQ:BMEA) has a market capitalization of $1.20 billion. The company earns $-81,830,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

How can I contact Biomea Fusion?

The official website for the company is www.biomeafusion.com. The company can be reached via phone at 650-980-9099 or via email at vsandwick@biomeafusion.com.

This page (NASDAQ:BMEA) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -